Noopept
Also known as: GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam
Overview
Noopept (GVS-111) is a synthetic dipeptide-derived nootropic compound that acts as a prodrug for cycloprolylglycine (CPG), an endogenous neuropeptide that modulates AMPA receptor function and has neurotrophic activity. Developed in Russia in the 1990s, Noopept is estimated to be approximately 1000 times more potent by weight than piracetam (though this comparison is mechanistically distinct). It is available as a prescription medication in Russia for cognitive disorders and widely used globally as a cognitive enhancer.
Mechanism of Action
After oral absorption, Noopept is cleaved to release cycloprolylglycine (CPG), which acts as an AMPA receptor modulator (ampakine activity) that enhances glutamatergic neurotransmission and promotes LTP (long-term potentiation). Additionally, Noopept stimulates BDNF and NGF expression in the hippocampus and cortex via TrkB receptor pathway sensitization. It also demonstrates anxiolytic activity through GABA-A receptor modulation and reduces oxidative stress in neuronal tissues. Alpha wave EEG activity is increased, associated with relaxed attention.
Potential Benefits
- Cognitive enhancement including memory consolidation and recall
- BDNF and NGF elevation in hippocampus
- Anxiolytic effects without sedation
- Neuroprotection in ischemia and excitotoxicity models
- Enhanced verbal memory and learning in clinical studies
- High oral bioavailability with rapid CNS penetration
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | 10 mg 1x daily |
| Intermediate | 10 mg 2x daily (morning/early afternoon) |
| Advanced | 10 mg 3x daily (do not exceed 30 mg) |
| Cycle Duration | 4-12 weeks with breaks |
Not a peptide — a proline-containing dipeptide prodrug (N-phenylacetyl-L-prolylglycine ethyl ester) converted to cycloprolylglycine. Russian racetam-class nootropic.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (capsule/tablet) Good — prodrug rapidly absorbed
Standard route. Take with or without food.
Sublingual (powder) Higher — bypasses first-pass
Commonly used form. Hold powder under tongue 30-60 seconds.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Noopept:
Nootropic Stack
Classic nootropic combination — Noopept 10-20 mg for BDNF/NGF, Alpha-GPC 300 mg for acetylcholine, PS 100 mg for membrane support.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Store capsules/tablets at room temperature in a dry, dark place. Liquid formulations refrigerated. |
|---|
Oral peptide — no reconstitution required. Follow product label for storage specifics.
Need exact syringe measurements?
Amino Acid Sequence
N-phenylacetyl-L-prolyl-glycine ethyl ester (prodrug for CPG dipeptide)
Side Effects & Safety
- Generally well-tolerated at recommended doses
- Headache (may indicate choline deficiency)
- Irritability or anxiety at high doses
- Mild nausea
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~30-60 minutes (parent); cycloprolylglycine metabolite longer |
|---|---|
| Storage | Store at room temperature (15-25°C) in a dry, dark place. Keep tightly closed. Do not refrigerate capsules. |
Synergistic Compounds
The following compounds have been studied alongside Noopept for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.